Abstract: The present invention is related to the field of bioprotection, in particular to the strain of Lactobacillus paracasei CHCC14676 with accession no. DSM25612. Furthermore, the present invention concerns an antifungal composition comprising the strain, an antifungal composition comprising the strain and at least one strain of Lactobacillus rhamnosus, food, feed and pharmaceutical products comprising such an antifungal composition, a method of manufacturing such food, feed and pharmaceutical products, a method for reducing the content of yeasts and molds of such food, feed and pharmaceutical products and uses of the antifungal composition.

Abstract: An implantable composition can include methacrylated solubilized devitalized cartilage (MeSDVC) with or without devitalized cartilage (DVC) particles. These compositions can be hydrogel precursors. After implantation, the MeSDVC may be crosslinked so as to form a hydrogel. The crosslinked hydrogel can include the DVC particles. A hydrogel precursor matrix (e.g., not crosslinked) can include a crosslinkable substance that can be crosslinked into a hydrogel, where DVC particles are included in the precursor matrix. The hydrogel precursor matrix can be located in a tissue defect site, such as a hole or recess in a cartilage or bone, and then crosslinked into a hydrogel that has the DVC particles therein.

Abstract: The invention is directed to a method for the in vitro production of arrangements of cell layers in which a first well (2.1) which is closed off from its environment except for a first inlet opening (4.1) and a first outlet opening (5.1) and which has as a first cell substrate (6.1) a first wall (2.1.1) and as a second cell substrate (6.2) an opposite, second wall (2.1.2) which is separated from the first wall (2.1.1) by a first gap, a free surface of a cell substrate (6.1, 6.2) to be colonized with cells is oriented orthogonal to the Earth's gravitational force, and cells (9) are adhered to the cell substrate (6.1, 6.2) to be colonized. The invention is further directed to a method of maintaining the biological functionalities of the cell layers and semi-finished products of a device for the in vitro production and culturing of cell layers and a method for the production of the device.

Abstract: A sensor determines whether a specimen includes a first substance. In an exemplary embodiment, the sensor includes a base. In an exemplary embodiment, the sensor is configured to determine whether the specimen includes the first substance and further includes, on the base, a detection unit on which a second substance is immobilized. The second substance includes a bond that is cleft by the reaction with hydrogen peroxide. In an exemplary embodiment, the specimen that is brought in contact with an enzyme that generates the hydrogen peroxide by the reaction with the first substance is introduced to the detection unit in the sensor configured to determine whether the specimen includes the first substance.

Abstract: This invention relates generally to method for producing products, particularly alcohols, by microbial fermentation. In particular, the invention relates to methods for increasing the efficiency of the fermentation, by providing a method for treating the used fermentation broth to produce a treated permeate which is then passed back to the bioreactor. The invention provides a method whereby at least one treatment step used to treat the permeated, produces a gaseous product which is then used in one or more stages of the fermentation process.

Abstract: The invention relates to a method for producing aniline or products that are obtained by further chemical reaction of aniline (aniline derivatives), involving decarboxylation of aminobenzoic acid, particularly ortho-aminobenzoic acid, in which one portion of the previously formed crude aniline is recirculated in the decarboxylation step. The aminobenzoic acid is obtained enzymatically or chemically, preferably enzymatically.

Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.

Abstract: Living cellular material may be preserved by incubating the cellular material in a culture medium containing at least one glycolipid, and then subjecting the cellular material to a preservation protocol.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: The present invention provides tissue scaffolds, methods of generating such scaffolds, and methods of use of such scaffolds to generate aligned and functional tissues for use in methods including regenerative medicine, wound repair and transplantation.

Abstract: Disclosed is a stable probiotic composition containing Bacillus coagulans MTCC 5856 exhibiting increased viability over wide range of pH and the use of flow cytometry method to enumerate the viable count of Bacillus coagulans MTCC 5856 under various environmental conditions.

Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.

Abstract: The present invention provides a method for efficiently inducing CD8-positive T cells by adding vitamin C to the medium in the steps of induction of the CD8-positive T cells from pluripotent stem cells. The present invention also provides a method for efficiently inducing CD8-positive T cells by performing culture in a medium supplemented with an adrenocortical hormone agent in the step of induction of the CD8-positive T cells from CD4/CD8 double-positive T cells.

Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

Abstract: The present invention is directed to methods of inducing spatial organization of cells an in vitro culture system using ultrasound technology. The invention is further directed to methods of inducing extracellular matrix remodeling and neovessel formation in an in vitro culture system and generating vascularized engineered tissue constructs using ultrasound technology.

Abstract: The present invention provides a technique which enables organization of bone marrow cells by a simple method in a short period of time. A method for preparing a bone marrow cell aggregate, comprising adding a liquid containing a bone marrow cell population to a medium containing a swellable material and culturing the bone marrow cell population in the presence of the swellable material. A method for reassembling a bone marrow tissue, comprising adding a liquid containing a bone marrow cell population to a medium containing a swellable material and culturing the bone marrow cell population in the presence of the swellable material. According to common knowledge in the art, it has been considered difficult to reorganize once disintegrated bone marrow tissue without changing the cell composition (that is, without adding any adherent cell or extracellular matrix which will work as a “connecting material (binder)”). Indeed, it was impossible to aggregate bone marrow cells by conventional methods.

Abstract: The invention relates to methods of differentiation, isolation, propagation, and storage of small colony variants (SCVs) of E. coli, preferably E. coli 83972 or E. coli HU2117, or modified or variant forms thereof, and methods for using the prepared SCV bacteria to establish probiotic biofilms in treated subjects and/or on treated medical devices.

Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.